Dendreon Shares Got Crushed: What You Need to Know

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Dendreon (Nasdaq: DNDN  ) plunged 18% on Monday after the company's quarterly results disappointed Wall Street.

So what: While Dendreon swung to a fourth-quarter profit of $38.1 million, a big revenue miss -- just $77 million versus the consensus of $121 million -- is forcing analysts to lower their growth expectations yet again. Slow adoption of its prostate cancer drug Provenge continues to weigh on sales, and judging from today's plunge, Wall Street doesn't expect things to turn anytime soon.

Now what: Not surprisingly, management also warned of slowing top-line growth in the current quarter. "Dendreon has embraced the challenge of introducing an entirely new treatment paradigm for an entirely new market and has made important progress towards establishing Provenge as the foundation of care," CEO John Johnson said. With the stock now down a whopping 70% from its April highs, Dendreon seems like decent opportunity for those who like to dig through the trash.

Interested in more info on Dendreon? Add it to your watchlist.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 27, 2012, at 2:25 PM, soho48 wrote:

    Where do you get your information on this company. Your information is many months old. The stock is not down due to an earnings miss. EPS were higher than recent estimates, it is down on the comments in the CC. Your bias re this company and acas are striking.

  • Report this Comment On February 27, 2012, at 5:17 PM, cvinfl wrote:

    I'm going to hold this. Seems like a prime takeover target.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1793427, ~/Articles/ArticleHandler.aspx, 12/18/2014 3:50:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement